Interleukin-12 gene therapy - Valentis

Drug Profile

Interleukin-12 gene therapy - Valentis

Latest Information Update: 19 Sep 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute; University of Pennsylvania; Valentis
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Interleukin 12 stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Head and neck cancer; Malignant melanoma

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-II for Head and neck cancer in USA (Intratumoural)
  • 19 Sep 2006 Discontinued - Phase-II for Malignant melanoma in USA (unspecified route)
  • 15 Jan 2002 Valentis reduces its preclinical product development efforts and suspends its programs in oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top